Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7JNHU)

• Drug Name: LAM-001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Lymphangioleiomyomatosis	CB07	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM7JNHU

Molecule-Related Drug Atlas

Drug(s) Targeting Serine/threonine-protein kinase mTOR (mTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sirolimus	DMGW1ID	Advanced cancer	2A00-2F9Z	Approved	[2]
Temsirolimus	DMS104F	Renal cell carcinoma	2C90	Approved	[3]
PF-04449913	DMSB068	Chronic myelomonocytic leukaemia	2A40	Approved	[4]
Everolimus	DM8X2EH	Advanced cancer	2A00-2F9Z	Approved	[5]
Novolimus	DM6ZPLQ	Artery stenosis	BD52	Approved	[6]
Zotarolimus	DMRMCXW	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Ridaforolimus	DMLHEU7	Sarcoma	2A60-2C35	Phase 3	[8]
AZD2014	DMOEARH	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[10]
PQR309	DMMCYZ8	Squamous head and neck cell carcinom	2D60.0	Phase 2	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [3] Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
• [7] Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
• [8] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [9] Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)